1. Mayo clinic. Skin cancer 2020 [cited 2020]. Available from: https://www.mayoclinic.org/diseases-conditions/skin-cancer/symptoms-causes/syc-20377605.
2. Apalla Z, Lallas A, Sotiriou E, Lazaridou E, Ioannides D. Epidemiological trends in skin cancer. Dermatol Pract Concept 2017; 7:1-6.
3. Mattia G, Puglisi R, Ascione B, Malorni W, Carè A, Matarrese P. Cell death-based treatments of melanoma: Conventional treatments and new therapeutic strategies. Cell Death Dis 2018; 9:112.
4. Domingues B, Lopes JM, Soares P, Pópulo H. Melanoma treatment in review. Immunotargets Ther 2018; 7:35-49.
5. Schadendorf D, van Akkooi AC, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. Lancet 2018; 392:971–984.
6. Gandini S, Autier P, Boniol M. Reviews on sun exposure and artificial light and melanoma. Prog Biophys Mol Biol 2011; 107:362–366.
7. Boniol M, Autier P, Boyle P, Gandini S. Cutaneous melanoma attributable to sunbed use: Systematic review and meta-analysis. BMJ 2012; 345.
8. Berwick M, Erdei E, Hay J. Melanoma epidemiology and public health. Dermatol Clin 2009; 27:205–214.
9. Flohil SC, van der Leest RJ, Arends LR, de Vries E, Nijsten T. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: A systematic review and meta-analysis. Eur J Cancer 2013; 49:2365–2375.
10. Eide MJ, Krajenta R, Johnson D, Long JJ, Jacobsen G, Asgari MM, et al. Identification of patients with nonmelanoma skin cancer using health maintenance organization claims data. Am J Epidemiol 2010; 171:123–128.
11. Wadhera A, Fazio M, Bricca G, Stanton O. Metastatic basal cell carcinoma: A case report and literature review. How accurate is our incidence data? Dermatol Online J 2006; 12:7.
12. Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26:v126–v132.
13. Li J, Wang Y, Liang R, An X, Wang K, Shen G, et al. Recent advances in targeted nanoparticles drug delivery to melanoma. Nanomedicine 2015; 11:769–794.
14. Rapozzi V, Jori G. Resistance to photodynamic therapy in cancer: Springer; 2014.
15. Widakowich C, de Castro Jr G, De Azambuja E, Dinh P, Awada A. Side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007; 12:1443–1455.
16. Austin E, Mamalis A, Ho D, Jagdeo J. Laser and light-based therapy for cutaneous and soft-tissue metastases of malignant melanoma: A systematic review. Arch Dermatol Res 2017; 309:229–242.
17. Krishnan V, Peng K, Sarode A, Prakash S, Zhao Z, Filippov SK, et al. Hyaluronic acid conjugates for topical treatment of skin cancer lesions. Sci Adv 2021; 7:eabe6627.
18. Lv Q, He C, Quan F, Yu S, Chen X. DOX/IL-2/IFN-γ co-loaded thermo-sensitive polypeptide hydrogel for efficient melanoma treatment. Bioact Mater 2018; 3:118–128.
19. Tupal A, Sabzichi M, Ramezani F, Kouhsoltani M, Hamishehkar H. Dermal delivery of doxorubicin-loaded solid lipid nanoparticles for the treatment of skin cancer. J Microencapsul 2016; 33:372–380.
20. Ahmed KS, Shan X, Mao J, Qiu L, Chen J. Derma roller® microneedles-mediated transdermal delivery of doxorubicin and celecoxib co-loaded liposomes for enhancing the anticancer effect. Mater Sci Eng C Mater Biol Appl 2019; 99:1448–1458.
21. Huber LA, Pereira TA, Ramos DN, Rezende LC, Emery FS, Sobral LM, et al. Topical skin cancer therapy using doxorubicin-loaded cationic lipid nanoparticles and iontophoresis. J Biomed Nanotechnol 2015; 11:1975–1988.
22. Wang W, Zhang P, Shan W, Gao J, Liang W. A novel chitosan-based thermosensitive hydrogel containing doxorubicin liposomes for topical cancer therapy. J Biomater Sci Polym Ed 2013; 24:1649–1659.
23. Smylie MG, Wong R, Mihalcioiu C, Lee C, Pouliot JF. A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma. Invest New Drugs 2007; 25:155–159.
24. Ugurel M, Schadendorf D, Fink W, Zimpfer-Rechner C, Thoelke A, Figl R, et al. Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma. Onkologie 2004; 27:540–544.
25. Vorobiof DA, Rapoport BL, Mahomed R, Karime M. Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment. Melanoma Res 2003; 13:201–203.
26. Wang J, Li Y, Wang L, Wang X, Tu P. Comparison of hyaluronic acid-based micelles and polyethylene glycol-based micelles on reversal of multidrug resistance and enhanced anticancer efficacy in vitro and in vivo. Drug Deliv 2018; 25:330–340.
27. Šmejkalová D, Muthný T, Nešporová K, Hermannová M, Achbergerová E, Huerta-Angeles G, et al. Hyaluronan polymeric micelles for topical drug delivery. Carbohydr Polym 2017; 156:86–96.
28. Abasalizadeh F, Moghaddam SV, Alizadeh E, akbari E, Kashani E, Fazljou SMB, et al. Alginate-based hydrogels as drug delivery vehicles in cancer treatment and their applications in wound dressing and 3D bioprinting. J Biol Eng 2020; 14:8.
29. Wei L, Cai C, Lin J, Chen T. Dual-drug delivery system based on hydrogel/micelle composites. Biomaterials 2009; 30:2606–2613.
30. Zang C, Tian Y, Tang Y, Tang M, Yang D, Chen F, et al. Hydrogel-based platforms for site-specific doxorubicin release in cancer therapy. J Transl Med 2024; 22:879.
31. Rakhshani N, Hassanzadeh Nemati N, Saadatabadi AR, Sadrnezhaad SK. Fabrication of novel poly(N-vinylcaprolactam)-coated UiO-66-NH2 metal organic framework nanocarrier for the controlled release of doxorubicin against A549 lung cancer cells. J Drug Del Sci Tech 2021; 66:102881.
32. Li W, Tao C, Wang J, Le Y, Zhang J. MMP-responsive in situ forming hydrogel loaded with doxorubicin-encapsulated biodegradable micelles for local chemotherapy of oral squamous cell carcinoma. RSC Adv 2019; 9:31264–31273.
33. Liu M, Song X, Wen Y, Zhu J-L, Li J. Injectable thermoresponsive hydrogel formed by alginate-g-poly(N-isopropylacrylamide) that releases doxorubicin-encapsulated micelles as a smart drug delivery system. ACS Appl Mater Interfaces 2017; 9:35673–35682.
34. Domiński A, Konieczny T, Godzierz M, Musioł M, Janeczek H, Foryś A, et al. Co-delivery of 8-Hydroxyquinoline glycoconjugates and doxorubicin by supramolecular hydrogel based on α-Cyclodextrin and pH-responsive micelles for enhanced tumor treatment. Pharmaceutics 2022; 14:2490.
35. Chung CK, García-Couce J, Campos Y, Kralisch D, Bierau K, Chan A, et al. Doxorubicin loaded poloxamer thermosensitive hydrogels: Chemical, pharmacological and biological evaluation. Molecules 2020; 25:2219.
36. Xi Y, Jiang T, Yu Y, Yu J, Xue M, Xu N, et al. Dual targeting curcumin loaded alendronate-hyaluronan- octadecanoic acid micelles for improving osteosarcoma therapy. Int J Nanomed 2019; 14:6425–6437.
37. Niu J, Yuan M, Zhang Z, Wang L, Fan Y, Liu X, et al. Hyaluronic acid micelles for promoting the skin permeation and deposition of curcumin. Int J Nanomed 2022; 17:4009–4022.
38. Lv S, Wu Y, Cai K, He H, Li Y, Lan M, et al. High drug loading and sub-quantitative loading efficiency of polymeric micelles driven by donor–receptor coordination interactions. J Am Chem Soc 2018; 140:1235–1238.
39. Szulc-Musioł B, Siemiradzka W, Dolińska B. Formulation and evaluation of hydrogels based on sodium alginate and cellulose derivatives with quercetin for topical application. Applied Sci 2023; 13:7826.
40. Xu M, Mou Y, Hu M, Dong W, Su X, Wu R, et al. Evaluation of micelles incorporated into thermosensitive hydrogels for intratumoral delivery and controlled release of docetaxel: A dual approach for in situ treatment of tumors. Asian J Pharm Sci 2018; 13:373–382.
41. Nie S, Hsiao WW, Pan W, Yang Z. Thermoreversible Pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies. Int J Nanomedicine 2011:151–166.
42. Kumari S, Alsaidan OA, Mohanty D, Zafar A, Das S, Gupta JK, et al. Development of soft luliconazole invasomes gel for effective transdermal delivery: Optimization to in-vivo antifungal activity. Gels 2023; 9:626.
43. Ma W, Guo Q, Li Y, Wang X, Wang J, Tu P. Co-assembly of doxorubicin and curcumin targeted micelles for synergistic delivery and improving anti-tumor efficacy. Eur J Pharm Biopharm 2017; 112:209–223.
44. Cho HJ, Yoon HY, Koo H, Ko SH, Shim JS, Lee JH, et al. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel. Biomaterials 2011; 32:7181–7190.
45. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006; 11:812–818.
46. Cuomo F, Cofelice M, Lopez F. Rheological characterization of hydrogels from alginate-based nanodispersion. Polymers (Basel) 2019; 11:259.
47. Cui C, Xue YN, Wu M, Zhang Y, Yu P, Liu L, et al. Cellular uptake, intracellular trafficking, and antitumor efficacy of doxorubicin-loaded reduction-sensitive micelles. Biomaterials 2013; 34:3858–3869.
48. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004; 56:603–618.
49. Witting M, Boreham A, Brodwolf R, Vávrová K, Alexiev U, Friess W, et al. Interactions of hyaluronic acid with the skin and implications for the dermal delivery of biomacromolecules. Mol Pharm 2015; 12:1391–1401.
50. Smejkalová D, Nešporová K, Hermannová M, Huerta-Angeles G, Cožíková D, Vištejnová L, et al. Paclitaxel isomerisation in polymeric micelles based on hydrophobized hyaluronic acid. Int J Pharm 2014; 466:147–155.
51. Yang Y, Sunoqrot S, Stowell C, Ji J, Lee C-W, Kim JW, et al. Effect of size, surface charge, and hydrophobicity of poly(amidoamine) dendrimers on their skin penetration. Biomacromolecules 2012; 13:2154–2162.
52. Cao H, Wang M, Ding J, Lin Y. Hydrogels: A promising therapeutic platform for inflammatory skin diseases treatment. J Mater Chem B 2024; 12:8007–8032.
53. Barati M, Mohammadi Samani S, Pourtalebi Jahromi L, Ashrafi H, Azadi A. Controlled-release in-situ gel forming formulation of tramadol containing chitosan-based pro-nanogels. Int J Biol Macromol 2018; 118:1449–1454.
54. Azadi A, Hamidi M, Rouini M-R. Methotrexate-loaded chitosan nanogels as ‘Trojan Horses’ for drug delivery to brain: Preparation and in vitro/in vivo characterization. Int J Biol Macromol 2013; 62:523–530.
55. Zang C, Tian Y, Tang Y, Tang M, Yang D, Chen F, et al. Hydrogel-based platforms for site-specific doxorubicin release in cancer therapy. J Transl Med 2024; 22:879.
56. Gill KK, Nazzal S, Kaddoumi A. Paclitaxel loaded PEG5000–DSPE micelles as pulmonary delivery platform: Formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur J Pharm Biopharm 2011; 79:276–284.
57. Alipour S, Shirazi HC, Kazemi M, Dehshahri A, Ahmadi F. Synthesis and cytotoxicity evaluation of doxorubicin-polyethyleneimine conjugate as a potential carrier for dual delivery of drug and gene. J Drug Deliv Sci Technol 2022; 68:102994.
58. Mansouri K, Ahmadi F, Dehshahri A. Synthesis of L-DOPA conjugated doxorubicin-polyethylenimine nanocarrier and evaluation of its cytotoxicity on A375 and HepG2 cell lines. Nanomed J 2021; 8:264-269.
59. Kazemi M, Parhizkar E, Samani SM, Firuzi O, Sadeghpour H, Ahmadi F, et al. Targeted co‐delivery of paclitaxel and anti P‐gp shRNA by low molecular weight PEI decorated with L‐3, 4‐dihydroxyphenylalanine. Biotechnol Prog 2023; 39:e3310.
)